InflaRx shares pop on FDA emergency use authorization of Covid-19 treatment injectionProactive Investors • 04/05/23
InflaRx Receives FDA Emergency Use Authorization for Gohibic (vilobelimab) for Treatment of Critically Ill COVID-19 PatientsGlobeNewsWire • 04/04/23
InflaRx Provides Update on Planned Phase III Study Design in Pyoderma Gangrenosum with Vilobelimab and Status of its EUA Application in Critically Ill COVID-19 PatientsGlobeNewsWire • 01/05/23
InflaRx Announces Amendment of Co-Development Agreement and Additional Equity Investment by Staidson in Connection with Regulatory Filing in China for Anti-C5a-Antibody for Treatment of COVID-19GlobeNewsWire • 12/21/22
InflaRx Initiates First-in-Human Study with Small Molecule C5aR Inhibitor INF904GlobeNewsWire • 11/09/22
InflaRx Submits Request for Emergency Use Authorization to US FDA for Vilobelimab for Treatment of Critically Ill COVID-19 PatientsGlobeNewsWire • 09/29/22
InflaRx Announces Vilobelimab Phase III Results in Critically Ill COVID-19 Patients Published in The Lancet Respiratory MedicineGlobeNewsWire • 09/08/22
InflaRx N.V. (IFRX) Upgraded to Buy: What Does It Mean for the Stock?Zacks Investment Research • 08/11/22
InflaRx Announces Plans to Apply for Emergency Use Authorization from the US FDA for Vilobelimab for Treatment of Critically Ill COVID-19 PatientsGlobeNewsWire • 07/26/22
InflaRx Receives FDA Fast Track Designation for Treatment of Ulcerative Pyoderma GangrenosumGlobeNewsWire • 07/06/22
InflaRx Provides Development Update for Vilobelimab in Pyoderma Gangrenosum and Severe COVID-19GlobeNewsWire • 06/29/22